Clinical trial
Trilostane for Androgen-Independent Prostate Cancer
NCT00181597 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00181597 |
|---|---|
| Title | Trilostane for Androgen-Independent Prostate Cancer |
| Official title | A Phase II Study of Trilostane for Androgen-Independent Prostate Cancer |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer, Prostate Adenocarcinoma |
| Intervention type | Drug |
| Interventions | Trilostane, Hydrocortisone |
| Enrollment | 24 |
| Start date | Mar 1, 2004 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Sep 16, 2005 |
| Last update posted | Dec 3, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: